CYP3A4, CYP3A5, and CYP4F2 Polymorphisms and Bleeding Risk in Ticagrelor-Based Dual Antiplatelet Therapy
<i>Background and Objectives</i>: Ticagrelor reduces ischemic events in acute coronary syndrome (ACS) but increases bleeding risk. Clinical predictors of bleeding are well established; the contribution of cytochrome P450 polymorphisms involved in ticagrelor metabolism remains uncertain, with conflic...
Na minha lista:
| Principais autores: | , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI AG
2026-06-01
|
| Serier: | Medicina |
| Fag: | |
| Online adgang: | https://www.mdpi.com/1648-9144/62/6/1202 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
